Adar1 Capital Management, Llc Purchases 934,258 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) Stock

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the business's stock in a transaction dated Wednesday, April 9th. The stock was acquired at an average cost of $10.13 per share, for a total transaction of $9,464,033.54. Following the transaction, the insider now owns 4,392,737 shares of the company's stock, valued at $44,498,425.81. This represents a 27.01 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.

Keros Therapeutics Stock Performance

NASDAQ KROS traded up $0.54 on Friday, hitting $14.07. The stock had a trading volume of 1,347,070 shares, compared to its average volume of 781,948. Keros Therapeutics, Inc. has a 52-week low of $9.12 and a 52-week high of $72.37. The company has a market capitalization of $570.71 million, a price-to-earnings ratio of -2.70 and a beta of 1.39. The firm has a 50-day moving average of $11.09 and a 200-day moving average of $29.78.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, beating analysts' consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $3.04 million during the quarter, compared to analyst estimates of $37.32 million. As a group, research analysts anticipate that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on KROS. Cantor Fitzgerald cut Keros Therapeutics from an "overweight" rating to a "neutral" rating in a report on Tuesday, January 21st. Guggenheim reiterated a "neutral" rating on shares of Keros Therapeutics in a research note on Friday, January 17th. Oppenheimer reduced their price objective on shares of Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating on the stock in a research note on Thursday, January 16th. Truist Financial lowered their price target on Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a report on Wednesday, April 9th. Finally, Piper Sandler dropped their price objective on shares of Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a research note on Friday, January 17th. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $40.33.

Hedge Funds Weigh In On Keros Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in KROS. Geode Capital Management LLC lifted its position in Keros Therapeutics by 6.8% in the 3rd quarter. Geode Capital Management LLC now owns 725,621 shares of the company's stock valued at $42,146,000 after acquiring an additional 46,041 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Keros Therapeutics during the fourth quarter valued at approximately $388,000. Barclays PLC raised its holdings in Keros Therapeutics by 140.1% in the 3rd quarter. Barclays PLC now owns 60,014 shares of the company's stock worth $3,484,000 after purchasing an additional 35,022 shares during the period. Norges Bank purchased a new position in shares of Keros Therapeutics during the 4th quarter valued at about $1,027,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in Keros Therapeutics during the fourth quarter valued at approximately $461,000. Institutional investors own 71.56% of the company's stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.